文献速递中枢神经肿瘤放疗乳腺癌放疗

循环肿瘤细胞与乳腺癌脑转移灶局部放疗后脑部疾病控制的关联前瞻性评估

Prospective Assessment of the Association Between Circulating Tumor Cells and Control of Brain Disease After Focal Radiation Therapy of Breast Cancer Brain Metastases.
PubMed 文献 · Adv Radiat Oncol · 2021-02-16

本研究前瞻性评估39例乳腺癌脑转移患者接受立体定向放疗/放射外科前后循环肿瘤细胞(CTC)与脑部疾病控制的关系。中位随访16.6个月,CTC1≤0.5 CTC/mL者6个月远处脑失败(DBF)为40%,CTC1>0.5者为8.82%(P=.007);多因素分析显示CTC1≤0.5与DBFFS和D-DBFFS较差相关。提示CTC1及NL/CTC1可能作为早期弥漫性DBF的生物标志物,并辅助选择局部或全脑放疗。

要点

  • CTC1≤0.5 CTC/mL者6个月DBF为40%,CTC1>0.5者为8.82%(P=.007)。
  • CTC1≤0.5与DBFFS(HR 8.27)和D-DBFFS(HR 10.22)较差独立相关。
  • CTC1及NL/CTC1可能辅助乳腺癌脑转移患者选择局部或全脑放疗。

核心结论

  • CTC1和NL/CTC1可能作为乳腺癌脑转移患者早期弥漫性远处脑失败的生物标志物,并指导后续选择局部或全脑放疗。

研究设计与样本

  • 前瞻性研究,纳入2016至2018年39例接受立体定向放疗/放射外科的乳腺癌脑转移患者,放疗前(CTC1)和放疗后4–5周(CTC2)定量分析CTC,中位随访16.6个月。

主要发现

  • 所有39例患者放疗前均检出CTC,35例放疗后患者中34例检出CTC。
  • 中位DBFFS、D-DBFFS和总生存分别为15.3、14.1和19.5个月。
  • 6个月DBF在CTC1≤0.5者为40%,CTC1>0.5者为8.82%(P=.007);D-DBF分别为40%和0(P=.005);NL/CTC1>6.8者为25%,≤6.8者为2.65%(P=.063)。
  • 多因素分析显示CTC1≤0.5者DBFFS较差(HR 8.27,95%CI 2.12–32.3,P=.002),D-DBFFS也较差(HR 10.22,95%CI 1.99–52.41,P=.005)。
  • COX2、EGFR、ST6GALNAC5、NOTCH1和HER2蛋白表达与结局无关。

关键数值与推荐

  • CTC1阈值为0.5 CTC/mL,NL/CTC1阈值为6.8。
  • 6个月DBF:CTC1≤0.5为40%,CTC1>0.5为8.82%(P=.007)。
  • 6个月D-DBF:CTC1≤0.5为40%,CTC1>0.5为0(P=.005);NL/CTC1>6.8为25%,≤6.8为2.65%(P=.063)。

临床怎么用

  • 对乳腺癌脑转移拟行局部放疗者,可考虑检测放疗前CTC1以辅助评估早期弥漫性远处脑失败风险。
  • CTC1≤0.5 CTC/mL提示DBFFS和D-DBFFS较差,可能需更密切随访或讨论全脑放疗策略。

局限性

  • 样本量较小(39例),放疗后CTC分析仅35例。
  • NL/CTC1与D-DBF的关联未达统计学显著性(P=.063)。
  • 蛋白表达与结局无关,未发现其他生物标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Predicting the risk of early distant brain failure (DBF) is in demand for management decisions in patients who are candidates for local treatment of brain metastases. This study aimed to analyze the association between circulating tumor cells (CTCs) and brain disease control after stereotactic radiation therapy/radiosurgery (SRT) for breast cancer brain metastasis (BCBM). METHODS AND MATERIALS: We prospectively assessed CTCs before (CTC1) and 4 to 5 weeks after (CTC2) SRT and their relationship with the number of new lesions (NL) suggestive of BCBM before SRT. CTC were quantified and analyzed by immunocytochemistry to evaluate the expression of the proteins COX2, EGFR, ST6GALNAC5, NOTCH1, and HER2. Distant brain failure-free survival (DBFFS), the primary endpoint, diffuse DBFFS (D-DBFFS), and overall survival were estimated. Analysis for DBF within 6 months, with death as competing risk, was performed. RESULTS: Patients were included between 2016 and 2018. CTCs were detected in all 39 patients before and in 34 of 35 patients after SRT. After median follow-up of 16.6 months, median DBFFS, D-DBFFS, and overall survival were 15.3, 14.1, and 19.5 months, respectively. DBF at 6 months was 40% with CTC1 ≤0.5 and 8.82% with CTC1 >0.5 CTC/mL (P = .007), and D-DBF at 6 months was 40% with CTC1 ≤0.5 and 0 with CTC1 >0.5 CTC/mL (P = .005) and 25% with NL/CTC1 >6.8 and 2.65% with NL/CTC1 ≤6.8 (P = .063). On multivariate analysis, DBFFS was inferior with CTC1 ≤0.5 (hazard ratio, 8.27; 95% confidence interval, 2.12-32.3; P = .002), and D-DBFFS was inferior with CTC1 ≤0.5 (hazard ratio, 10.22; 95% confidence interval, 1.99-52.41; P = .005). Protein expression was not associated with outcomes. CONCLUSIONS: These data suggest that CTC1 and NL/CTC1 may have a role as a biomarker of early diffuse DBF and as a subsequent guide between focal or whole-brain radiation therapy in patients with BCBM.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Guedes de Castro D, Braun AC, Calsavara VF, et al. Prospective Assessment of the Association Between Circulating Tumor Cells and Control of Brain Disease After Focal Radiation Therapy of Breast Cancer Brain Metastases. Adv Radiat Oncol. 2021. PMID: 33912738. doi:10.1016/j.adro.2021.100673

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。